RU2007120431A - PHARMACEUTICAL COMPOSITION OF PROXODOLOL WITH CONTROLLED RELEASE - Google Patents
PHARMACEUTICAL COMPOSITION OF PROXODOLOL WITH CONTROLLED RELEASE Download PDFInfo
- Publication number
- RU2007120431A RU2007120431A RU2007120431/15A RU2007120431A RU2007120431A RU 2007120431 A RU2007120431 A RU 2007120431A RU 2007120431/15 A RU2007120431/15 A RU 2007120431/15A RU 2007120431 A RU2007120431 A RU 2007120431A RU 2007120431 A RU2007120431 A RU 2007120431A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- proxodolol
- following number
- pharmacologically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 21
- 238000013270 controlled release Methods 0.000 title claims abstract 3
- IQEOUWNTUSFDSZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy]propan-2-ol;hydrochloride Chemical group Cl.COC1=NOC(COC=2C(=CC=CC=2)OCC(O)CNC(C)(C)C)=N1 IQEOUWNTUSFDSZ-UHFFFAOYSA-N 0.000 title 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 7
- 229960003943 hypromellose Drugs 0.000 claims abstract 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract 6
- 229920002678 cellulose Chemical class 0.000 claims abstract 6
- 239000001913 cellulose Chemical class 0.000 claims abstract 6
- 235000010980 cellulose Nutrition 0.000 claims abstract 6
- 235000002639 sodium chloride Nutrition 0.000 claims abstract 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 5
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims abstract 5
- 239000008116 calcium stearate Substances 0.000 claims abstract 5
- 235000013539 calcium stearate Nutrition 0.000 claims abstract 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000013543 active substance Substances 0.000 claims abstract 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 4
- 239000011780 sodium chloride Substances 0.000 claims abstract 4
- 239000000126 substance Substances 0.000 claims abstract 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract 3
- 229920002125 Sokalan® Chemical class 0.000 claims abstract 3
- 229920001817 Agar Chemical class 0.000 claims abstract 2
- 229920000945 Amylopectin Chemical class 0.000 claims abstract 2
- 241000416162 Astragalus gummifer Species 0.000 claims abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract 2
- 239000004375 Dextrin Substances 0.000 claims abstract 2
- 229920001353 Dextrin Polymers 0.000 claims abstract 2
- 108010010803 Gelatin Proteins 0.000 claims abstract 2
- 241000206672 Gelidium Species 0.000 claims abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract 2
- 239000004471 Glycine Substances 0.000 claims abstract 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 2
- 229930195725 Mannitol Natural products 0.000 claims abstract 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract 2
- 229920002472 Starch Polymers 0.000 claims abstract 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract 2
- 229930006000 Sucrose Natural products 0.000 claims abstract 2
- 229920001615 Tragacanth Chemical class 0.000 claims abstract 2
- 235000010419 agar Nutrition 0.000 claims abstract 2
- 235000010443 alginic acid Nutrition 0.000 claims abstract 2
- 229920000615 alginic acid Chemical class 0.000 claims abstract 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract 2
- 229960001631 carbomer Drugs 0.000 claims abstract 2
- 229960000913 crospovidone Drugs 0.000 claims abstract 2
- 235000019425 dextrin Nutrition 0.000 claims abstract 2
- 239000008273 gelatin Substances 0.000 claims abstract 2
- 229920000159 gelatin Polymers 0.000 claims abstract 2
- 235000019322 gelatine Nutrition 0.000 claims abstract 2
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract 2
- 239000008103 glucose Substances 0.000 claims abstract 2
- 235000001727 glucose Nutrition 0.000 claims abstract 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract 2
- 239000008101 lactose Substances 0.000 claims abstract 2
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract 2
- 239000000594 mannitol Substances 0.000 claims abstract 2
- 235000010355 mannitol Nutrition 0.000 claims abstract 2
- 229920001223 polyethylene glycol Chemical class 0.000 claims abstract 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000000741 silica gel Substances 0.000 claims abstract 2
- 229910002027 silica gel Inorganic materials 0.000 claims abstract 2
- 239000000377 silicon dioxide Substances 0.000 claims abstract 2
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract 2
- 239000000600 sorbitol Substances 0.000 claims abstract 2
- 235000010356 sorbitol Nutrition 0.000 claims abstract 2
- 239000008107 starch Substances 0.000 claims abstract 2
- 235000019698 starch Nutrition 0.000 claims abstract 2
- 239000005720 sucrose Substances 0.000 claims abstract 2
- 230000008961 swelling Effects 0.000 claims abstract 2
- 239000000454 talc Substances 0.000 claims abstract 2
- 229910052623 talc Inorganic materials 0.000 claims abstract 2
- 239000004408 titanium dioxide Substances 0.000 claims abstract 2
- 235000010215 titanium dioxide Nutrition 0.000 claims abstract 2
- 239000000196 tragacanth Chemical class 0.000 claims abstract 2
- 235000010487 tragacanth Nutrition 0.000 claims abstract 2
- 229940116362 tragacanth Drugs 0.000 claims abstract 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 3
- 229910052710 silicon Inorganic materials 0.000 claims 3
- 239000010703 silicon Substances 0.000 claims 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical class COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Фармацевтическая композиция с контролируемым высвобождением, содержащая активное вещество и носитель, отличающаяся тем, что в качестве активного вещества она содержит эффективное количество проксодолола или его фармацевтически приемлемой соли, а в качестве носителя - смесь набухающего или гелеобразующего компонента и фармакологически приемлемого наполнителя.2. Фармацевтическая композиция по п.1, отличающаяся тем, что в качестве набухающего или гелеобразующего компонента она содержит поливинилпирролидон, полимеры акриловой кислоты, полиэтиленгликоли, альгинаты, карбомер, амилопектин, агар-агар, трагакант, целлюлозу, производные целлюлозы или смесь указанных веществ.3. Фармацевтическая композиция по п.2, отличающаяся тем, что в качестве производных целлюлозы, она содержит гидроксипропилцеллюлозу, в частности гипромеллозу.4. Фармацевтическая композиция по п.2, отличающаяся тем, что в качестве фармакологически приемлемого наполнителя, она содержит как минимум одно вещество, выбранное из группы: декстрин, лактоза, целлюлоза микрокристаллическая, кальция стеарат, кремний диоксид, сахароза, глюкоза, натрия хлорид, крахмал, натрия гидрокарбонат, кросповидон, магния стеарат, силикагель, натрия хлорид, тальк, глицин, полиэтиленоксид, желатин, маннит, сорбит, титана диоксид.5. Фармацевтическая композиция по любому из пп.1-4, отличающаяся тем, что она содержит следующее количество компонентов, мас.%:6. Фармацевтическая композиция по п.5, отличающаяся тем, что она содержит следующее количество компонентов, мас.%:7. Фармацевтическая композиция по любому из пп.1-4, отличающаяся тем, что она содержит следующее количество ко1. A controlled-release pharmaceutical composition containing an active substance and a carrier, characterized in that it contains an effective amount of proxodolol or a pharmaceutically acceptable salt thereof as an active substance, and a mixture of a swellable or gel-forming component and a pharmacologically acceptable excipient as a carrier. The pharmaceutical composition according to claim 1, characterized in that it contains polyvinylpyrrolidone, polymers of acrylic acid, polyethylene glycols, alginates, carbomer, amylopectin, agar-agar, tragacanth, cellulose, cellulose derivatives or a mixture of these substances as a swelling or gelling component. The pharmaceutical composition according to claim 2, characterized in that, as cellulose derivatives, it contains hydroxypropyl cellulose, in particular hypromellose. The pharmaceutical composition according to claim 2, characterized in that as a pharmacologically acceptable excipient, it contains at least one substance selected from the group: dextrin, lactose, microcrystalline cellulose, calcium stearate, silicon dioxide, sucrose, glucose, sodium chloride, starch, sodium bicarbonate, crospovidone, magnesium stearate, silica gel, sodium chloride, talc, glycine, polyethylene oxide, gelatin, mannitol, sorbitol, titanium dioxide. 5. The pharmaceutical composition according to any one of claims 1 to 4, characterized in that it contains the following number of components, wt.%: 6. The pharmaceutical composition according to claim 5, characterized in that it contains the following number of components, wt.%: 7. The pharmaceutical composition according to any one of claims 1 to 4, characterized in that it contains the following amount of
Claims (13)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007120431/15A RU2356532C2 (en) | 2007-06-01 | 2007-06-01 | Controlled-release pharmaceutical proxodolol composition |
| PCT/RU2007/000619 WO2008147245A2 (en) | 2007-06-01 | 2007-11-13 | Controlled release proxodolol pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007120431/15A RU2356532C2 (en) | 2007-06-01 | 2007-06-01 | Controlled-release pharmaceutical proxodolol composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007120431A true RU2007120431A (en) | 2008-12-10 |
| RU2356532C2 RU2356532C2 (en) | 2009-05-27 |
Family
ID=40075688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007120431/15A RU2356532C2 (en) | 2007-06-01 | 2007-06-01 | Controlled-release pharmaceutical proxodolol composition |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2356532C2 (en) |
| WO (1) | WO2008147245A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012121998A1 (en) * | 2011-03-04 | 2012-09-13 | Becton, Dickinson And Company | Blood collection device containing lysophospholipase inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA959221B (en) * | 1994-11-02 | 1997-04-30 | Janssen Pharmaceutica Nv | Cisapride extended release |
| CO5140079A1 (en) * | 1998-10-14 | 2002-03-22 | Novartis Ag | PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT |
| GB0227948D0 (en) * | 2002-11-29 | 2003-01-08 | Cipla Ltd | Pharmaceutical combinations comprising b-2 adrenoreceptor agonists and xanthines |
| RU2248206C1 (en) * | 2003-06-30 | 2005-03-20 | Федеральное государственное унитарное предприятие "Центр по химии лекарственных средств" (ФГУП ЦХЛС-ВНИХФИ) | Medicinal preparation for treatment of chronic cardiac insufficiency |
-
2007
- 2007-06-01 RU RU2007120431/15A patent/RU2356532C2/en active
- 2007-11-13 WO PCT/RU2007/000619 patent/WO2008147245A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2356532C2 (en) | 2009-05-27 |
| WO2008147245A3 (en) | 2009-06-04 |
| WO2008147245A2 (en) | 2008-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2593582T3 (en) | Coated tablet formulation and method | |
| US10786507B2 (en) | Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof | |
| KR100699958B1 (en) | Pharmaceutical compositions comprising terbinafine and uses thereof | |
| AU2006263338A1 (en) | Pharmaceutical sustained release compositions and processes thereof | |
| ES3033466T3 (en) | Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate | |
| JP2009545560A5 (en) | ||
| WO2015156581A1 (en) | Pharmaceutical composition containing pregabalin with improved stability and method for preparing same | |
| RU2015107517A (en) | PHARMACEUTICAL COMPOSITIONS OF MEMANTINE | |
| BG65773B1 (en) | Orally applicable tablet matrix for sustained release of trimetazidine | |
| CN1178659C (en) | Pharmaceutical formulations with controlled release of active compounds | |
| KR20080048461A (en) | Gastrointestinal retention agent and preparation method thereof | |
| PL203710B1 (en) | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | |
| US20170258749A1 (en) | Oseltamivir Compositions | |
| US20190110994A1 (en) | Pharmaceutical composition of dapagliflozin | |
| RU2008110489A (en) | PHARMACEUTICAL COMPOSITION OF METFORMIN WITH LONG-LAST RELEASE AND METHOD FOR PRODUCING IT | |
| RU2007120431A (en) | PHARMACEUTICAL COMPOSITION OF PROXODOLOL WITH CONTROLLED RELEASE | |
| WO2014193528A1 (en) | Amorphous dosage forms and methods | |
| US20080015188A1 (en) | Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives | |
| US20120122993A1 (en) | Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-(1r)-, methanesulfonate | |
| CN1832736A (en) | Stable extended-release oral dosage form of gabapentin | |
| WO2011093828A2 (en) | Solid dosage forms comprising cefprozil | |
| RU2008115582A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE | |
| WO2021091498A1 (en) | Pharmaceutical compositions comprising tenofovir and emtricitabine | |
| RU2012131509A (en) | FAST-PHARMACEUTICAL COMPOSITION CONTAINING LORNOXICA | |
| WO2017037645A1 (en) | Stable pharmaceutical formulations of teriflunomide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner |